HERE Technologies deepens collaboration with China’s intelligent driving innovator neueHCT to accelerate global NOA expansion
CTF Life Launches MyWealth Beyond Savings Insurance Plan
6 Ways to Avoid Hidden Fees When Spending Overseas
China Chunlai Announces 2026 Interim Results
FREELANDER 8 Production-Intent Show Model Makes Global Debut: First Complete Look at the Legend Reborn
-Translational analysis of patients that do not respond to PD-(L)1 inhibitors show high pretreatment intratumoral…
Collaboration with Precision for Medicine to develop novel flow cytometry PD-1 expression assay as a…
ZUG, Switzerland and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP),…
Inivata Presents New Data in Support of its Liquid Biopsy Technologies at AACR Virtual Annual…
– exoASO™-STAT6 mediated genetic reprogramming of tumor associated macrophages results in potent single-agent anti-tumor activity…
Pro-tumor effects detected as early as four days after Inhibigen administration Insights into Inhibigen biology…
Xerna™ TME Panel describes the tumor microenvironment based on dominant biology subtypes with prognostic capabilities…
BELTSVILLE, Md., April 10, 2021 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical…
LONDON, April 10, 2021 (GLOBE NEWSWIRE) — Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical…
SOUTH SAN FRANCISCO, Calif., April 10, 2021 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (NASDAQ: HARP),…
Initial data from the Phase 1 dose escalation part of the Phase 1/2a trial in…
~ Preclinical data show the utility of Gennao’s proprietary first-in-class monoclonal antibody 3E10-D31N (GMABD31N), a…
ROCKVILLE, MD, April 10, 2021 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused…
MYC genomic amplification found to be a key driver of sensitivity to CDK9 inhibition Pan-cancer…
Proprietary TurboCAR Technology Platform Allows Cytokine Activation Signaling to be Selectively Engineered into AlloCAR T™ Cells…
CAMBRIDGE, Mass. and NEW YORK, April 10, 2021 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc….
Bolt’s first-in-class clinical candidate, BDC-1001, is a novel HER2-targeting, TLR 7/8 immune-stimulating antibody conjugate (ISAC)…
KT-413-mediated degradation of IRAK4 and IMiD substrates has synergistic effect on MYD88-NFkB and IRF4-Type 1…
VANCOUVER, BC / ACCESSWIRE / April 10, 2021 / ELSE NUTRITION HOLDINGS INC. (TSXV:BABY)(OTCQX:BABYF)(FSE:0YL) (“Else”…
Additional, ongoing confirmed durable partial response and three additional patients with stable disease as best…